Immix Biopharma Statistics
Total Valuation
Immix Biopharma has a market cap or net worth of $275.60 million. The enterprise value is $260.76 million.
Important Dates
The last earnings date was Friday, November 7, 2025, after market close.
| Earnings Date | Nov 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Immix Biopharma has 52.70 million shares outstanding. The number of shares has increased by 15.04% in one year.
| Current Share Class | 52.70M |
| Shares Outstanding | 52.70M |
| Shares Change (YoY) | +15.04% |
| Shares Change (QoQ) | +6.48% |
| Owned by Insiders (%) | 12.90% |
| Owned by Institutions (%) | 8.17% |
| Float | 41.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 20.90 |
| P/TBV Ratio | 33.35 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.53, with a Debt / Equity ratio of 0.13.
| Current Ratio | 1.53 |
| Quick Ratio | 1.47 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -182.55% and return on invested capital (ROIC) is -107.32%.
| Return on Equity (ROE) | -182.55% |
| Return on Assets (ROA) | -66.48% |
| Return on Invested Capital (ROIC) | -107.32% |
| Return on Capital Employed (ROCE) | -260.57% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.12M |
| Employee Count | 21 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Immix Biopharma has paid $37,243 in taxes.
| Income Tax | 37,243 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +120.76% in the last 52 weeks. The beta is 0.33, so Immix Biopharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.33 |
| 52-Week Price Change | +120.76% |
| 50-Day Moving Average | 4.57 |
| 200-Day Moving Average | 2.80 |
| Relative Strength Index (RSI) | 48.68 |
| Average Volume (20 Days) | 1,513,746 |
Short Selling Information
The latest short interest is 1.75 million, so 3.31% of the outstanding shares have been sold short.
| Short Interest | 1.75M |
| Short Previous Month | 1.37M |
| Short % of Shares Out | 3.31% |
| Short % of Float | 4.16% |
| Short Ratio (days to cover) | 1.34 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -24.05M |
| Pretax Income | -23.53M |
| Net Income | -23.56M |
| EBITDA | -23.84M |
| EBIT | -24.05M |
| Earnings Per Share (EPS) | -$0.78 |
Full Income StatementBalance Sheet
The company has $15.95 million in cash and $1.11 million in debt, giving a net cash position of $14.84 million or $0.28 per share.
| Cash & Cash Equivalents | 15.95M |
| Total Debt | 1.11M |
| Net Cash | 14.84M |
| Net Cash Per Share | $0.28 |
| Equity (Book Value) | 8.26M |
| Book Value Per Share | 0.25 |
| Working Capital | 5.73M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$14.38 million and capital expenditures -$1.07 million, giving a free cash flow of -$15.45 million.
| Operating Cash Flow | -14.38M |
| Capital Expenditures | -1.07M |
| Free Cash Flow | -15.45M |
| FCF Per Share | -$0.29 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Immix Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -15.04% |
| Shareholder Yield | -15.04% |
| Earnings Yield | -8.55% |
| FCF Yield | -5.61% |
Analyst Forecast
The average price target for Immix Biopharma is $12.00, which is 130.33% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $12.00 |
| Price Target Difference | 130.33% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
